Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

PEMIGATINIB for Malignant lymphoid neoplasm: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 7 adverse event reports in the FDA FAERS database where PEMIGATINIB was used for Malignant lymphoid neoplasm.

Most Reported Side Effects for PEMIGATINIB

Side Effect Reports % Deaths Hosp.
Off label use 114 16.1% 28 19
Disease progression 103 14.5% 38 13
Death 76 10.7% 76 6
Fatigue 72 10.2% 5 7
Alopecia 53 7.5% 2 5
Hyperphosphataemia 46 6.5% 10 11
Cholangiocarcinoma 44 6.2% 19 4
Diarrhoea 42 5.9% 0 10
Constipation 37 5.2% 2 4
Drug ineffective 37 5.2% 13 3
Hospitalisation 35 4.9% 0 34
Nausea 35 4.9% 5 5
Decreased appetite 34 4.8% 3 5
Stomatitis 31 4.4% 2 6
Dry mouth 30 4.2% 1 2

Other Indications for PEMIGATINIB

Cholangiocarcinoma (431) Bile duct cancer (34) Glioblastoma (12) Adenocarcinoma of salivary gland (10) Pancreatic carcinoma (8) Bladder cancer (6) Hepatic cancer (5) Myeloproliferative neoplasm (5) Neoplasm malignant (5)

Other Drugs Used for Malignant lymphoid neoplasm

RITUXIMAB (118) LENALIDOMIDE (31) CYCLOPHOSPHAMIDE (23) PREDNISOLONE (19) DABRAFENIB (18) BENDAMUSTINE (17) TRAMETINIB DIMETHYL SULFOXIDE (17) VINCRISTINE (16) METHOTREXATE (15) CARMUSTINE (14)

Related Pages

PEMIGATINIB Full Profile All Malignant lymphoid neoplasm Drugs PEMIGATINIB Demographics PEMIGATINIB Timeline